These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27748523)

  • 61. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
    Durie BG; Salmon SE; Mundy GR
    Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An overview of pim kinase as a target in multiple myeloma.
    Liu Z; Zhang Y; Guo Y; Wang H; Fu R
    Cancer Med; 2023 May; 12(10):11746-11759. PubMed ID: 37162273
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of CCN4 Function in Osteogenic and Osteoclastic Cells Using Gain and Loss of Function Approaches.
    Maeda A; Young M; Ono M
    Methods Mol Biol; 2017; 1489():347-359. PubMed ID: 27734388
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Involvement of PIM-1 in DNA fragmentation in mouse NS-1-derived cells.
    Takahashi C; Harada Y; Ariga H; Iguchi-Ariga SM
    Biochem Biophys Res Commun; 1995 Oct; 215(2):538-46. PubMed ID: 7487989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma.
    Cohen-Solal ME; Roux C; Valentin-Opran A; Dougados M; Amor B; De Vernejoul MC
    Bone; 1993; 14(3):505-9. PubMed ID: 8363900
    [No Abstract]   [Full Text] [Related]  

  • 66. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
    Haas M; Caron G; Chatonnet F; Manenti S; Alaterre E; Devin J; Delaloy C; Bertolin G; Viel R; Pignarre A; Llamas-Gutierrez F; Marchalot A; Decaux O; Tarte K; Delpy L; Moreaux J; Fest T
    Blood; 2022 Apr; 139(15):2316-2337. PubMed ID: 35108359
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
    Pozzi S; Fulciniti M; Yan H; Vallet S; Eda H; Patel K; Santo L; Cirstea D; Hideshima T; Schirtzinge L; Kuhstoss S; Anderson KC; Munshi N; Scadden D; Kronenberg HM; Raje N
    Bone; 2013 Apr; 53(2):487-96. PubMed ID: 23333523
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption.
    Tang CC; Castro Andrade CD; O'Meara MJ; Yoon SH; Sato T; Brooks DJ; Bouxsein ML; Martins JDS; Wang J; Gray NS; Misof B; Roschger P; Blouin S; Klaushofer K; Velduis-Vlug A; Vegting Y; Rosen CJ; O'Connell D; Sundberg TB; Xavier RJ; Ung P; Schlessinger A; Kronenberg HM; Berdeaux R; Foretz M; Wein MN
    Elife; 2021 Jun; 10():. PubMed ID: 34160349
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.
    Hebron E; Hope C; Kim J; Jensen JL; Flanagan C; Bhatia N; Maroulakou I; Mitsiades C; Miyamoto S; Callander N; Hematti P; Asimakopoulos F
    Br J Haematol; 2013 Mar; 160(6):779-84. PubMed ID: 23252623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.
    Raje N; Anderson KC
    Blood; 2000 Jul; 96(2):381-3. PubMed ID: 10887095
    [No Abstract]   [Full Text] [Related]  

  • 71. Immunohistochemical localization of phosphorylated AKT in multiple myeloma.
    Alkan S; Izban KF
    Blood; 2002 Mar; 99(6):2278-9. PubMed ID: 11902142
    [No Abstract]   [Full Text] [Related]  

  • 72. Buettner R, Morales C, Caserta E, et al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019;3(7):1027-1032.
    Blood Adv; 2022 Nov; 6(21):5797. PubMed ID: 36349910
    [No Abstract]   [Full Text] [Related]  

  • 73. A new insight into the formation of osteolytic lesions in multiple myeloma.
    Glass DA; Patel MS; Karsenty G
    N Engl J Med; 2003 Dec; 349(26):2479-80. PubMed ID: 14695406
    [No Abstract]   [Full Text] [Related]  

  • 74. Pinning down myeloma with Pim2 inhibitors!
    Neri P; Bahlis NJ
    Blood; 2013 Aug; 122(9):1534-6. PubMed ID: 23990611
    [No Abstract]   [Full Text] [Related]  

  • 75. Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis.
    Kristensen IB; Haaber J; Lyng MB; Knudsen LM; Rasmussen T; Ditzel HJ; Abildgaard N
    Leuk Lymphoma; 2013 Feb; 54(2):425-7. PubMed ID: 22742577
    [No Abstract]   [Full Text] [Related]  

  • 76. Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.
    Tanimoto K; Hiasa M; Tenshin H; Teramachi J; Oda A; Harada T; Higa Y; Sogabe K; Oura M; Sumitani R; Hara T; Endo I; Matsumoto T; Tanaka E; Abe M
    Haematologica; 2022 Mar; 107(3):744-749. PubMed ID: 34788982
    [No Abstract]   [Full Text] [Related]  

  • 77. MK2 is a therapeutic target for high-risk multiple myeloma.
    Gu C; Cheng H; Yang H; Bian Y; Wang Y; Zhang Y; Pisano M; Hu G; Yang Y
    Haematologica; 2021 Jun; 106(6):1774-1777. PubMed ID: 29567777
    [No Abstract]   [Full Text] [Related]  

  • 78. Skeletal reactions to neoplasms.
    Raisz LG; Mundy GR; Luben RA
    Ann N Y Acad Sci; 1974; 230():473-5. PubMed ID: 4207275
    [No Abstract]   [Full Text] [Related]  

  • 79. [Pim inhibitor].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():349-54. PubMed ID: 30615399
    [No Abstract]   [Full Text] [Related]  

  • 80. [Impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():185-9. PubMed ID: 30615343
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.